A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L+Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States

被引：0
|
作者：
Watson, Lucy [1 ]
Harrison, Owen [1 ]
Cockrum, Paul [2 ]
Veazey, Kylee [2 ]
Gaugris, Sabine [1 ]
Kim, George [3 ]
机构：
[1] FIECON, St Albans, England
[2] Ipsen, Cambridge, MA USA
[3] Mayo Clin Florida, Div Hematol & Oncol, Jacksonville, FL USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
IBCL; tazemetostat; relapsed/refractory follicular lymphoma; R/R FL; budget impact; cost saving;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-461
引用
收藏
页码：S498 / S499
页数：2
相关论文
共 50 条
  • [1] A BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF MOSUNETUZUMAB FOR TREATMENT OF THIRD- OR HIGHER-LINE (3L+) RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) IN THE UNITED STATES (US)
    Lin, S. W.
    Shapouri, S.
    Parise, H.
    Bercaw, E.
    Wu, M.
    Matasar, M.
    VALUE IN HEALTH, 2023, 26 (06) : S87 - S87
  • [2] BUDGET IMPACT ANALYSIS OF ZANUBRUTINIB plus OBINUTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN THE UNITED STATES
    Gaballa, S.
    Campbell, D.
    Xue, M.
    Wu, F.
    Massoudi, M.
    Migliaccio-Walle, K.
    Yang, K.
    VALUE IN HEALTH, 2024, 27 (06) : S92 - S92
  • [3] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Bell, Jill A.
    Cherepanov, Dasha
    Revicki, Dennis
    Speck, Rebecca M.
    Swett, Laura
    Stumpo, Kate
    Rong, Yuanxin
    Gordon, Leo I.
    QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
  • [4] A Budget Impact Analysis of the Introduction of Copanlisib for Treatment of Relapsed Follicular Lymphoma in the United States
    Appukkuttan, Sreevalsa
    Duchesneau, Emilie
    Zichlin, Miriam L.
    Bhak, Rachel H.
    Yaldo, Avin
    Gharibo, Mecide
    Babajanyan, Svetlana
    Duh, Mei Sheng
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (04): : 437 - +
  • [5] A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Third-or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)
    Matasar, Matthew
    Alvarez, Javier Sanchez
    Parise, Helene
    Zuk, Eric
    Di Maio, Danilo
    Shapouri, Sheila
    Kim, Eunice
    Lin, Shih-Wen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S455 - S456
  • [6] A COST-EFFECTIVENESS ANALYSIS OF MOSUNETUZUMAB FOR TREATMENT OF THIRD- OR HIGHER-LINE RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) IN THE UNITED STATES (US)
    Matasar, M.
    Alvarez, Sanchez J.
    Parise, H.
    Zuk, E.
    Di Maio, D.
    Shapouri, S.
    Lin, S. W.
    VALUE IN HEALTH, 2023, 26 (06) : S153 - S153
  • [7] Tazemetostat in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Propensity Score-Matched Analysis of E7438-G000-101 Trial Outcomes
    Proudman, David
    Gupta, Deepshekhar
    Nellesen, Dave
    Wong, Alex
    Yang, Jay
    Kamp, Beth
    Mamlouk, Khalid
    Cheson, Bruce
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S403 - S403
  • [8] Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    Pagel, John
    Morschhauser, Franck
    Herve, Tilly
    Chaidos, Aristeidis
    Phillips, Tycel
    Ribrag, Vincent
    Campbell, Phillip
    Fruchart, Christophe
    Jurczak, Wojciech
    McKay, Pamela
    Opat, Stephen
    Radford, John
    McDonald, Alice
    Howell, Haley
    Newberry, Kate
    Woodruff, Mark
    Clawson, Alicia
    Larus, John
    Blakemore, Stephen
    Miao, Harry
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S278 - S279
  • [9] HUMANISTIC BURDEN IN RELAPSED OR REFRACTORY (R/ R) FOLLICULAR LYMPHOMA (FL): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Forbes, C.
    Pustulka, I
    Nunez-Gonzalez, S.
    Kumar, J.
    VALUE IN HEALTH, 2023, 26 (12) : S451 - S452
  • [10] Tazemetostat (TAZ) in relapsed/refractory (R/R) follicular lymphoma (FL): Propensity-score matched analysis of E7438-G000-101 trial outcomes.
    Proudman, David
    Gupta, Deepshekhar
    Nellesen, Dave
    Wong, Alex
    Yang, Jay
    Kamp, Beth
    Mamlouk, Khalid
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345